Abstract
There is accumulating evidence that the nucleus accumbens (NAc) plays an important role in the pathophysiology of depression. Given that clinical depression is marked by anhedonia (diminished interest or pleasure), dysfunction of the brain reward pathway has been suggested as contributing to the pathophysiology of depression. Since the NAc is the center of reward and learning, it is hypothesized that anhedonia might be produced by hampering the function of the NAc. Indeed, it has been reported that stress, drug exposure and drug withdrawal, all of which produce a depressive-phenotype, alter various functions within the NAc, leading to inhibited dopaminergic activity in the NAc. In this review, we describe various factors as possible candidates within the NAc for the initiation of depressive symptoms. First, we discuss the roles of several neurotransmitters and neuropeptides in the functioning of the NAc, including dopamine, glutamate, γ-aminobutyric acid (GABA), acetylcholine, serotonin, dynorphin, enkephaline, brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), melanin-concentrating hormone (MCH) and cocaine- and amphetamine-regulated transcript (CART). Second, based on previous studies, we propose hypothetical relationships among these substances and the shell and core subregions of the NAc.
Keywords: Depression, nucleus accumbens, glutamate, dopamine, γ-aminobutyric acid (GABA), acetylcholine, dynorphin, cAMP response element-binding protein (CREB)
Current Neuropharmacology
Title: Neurochemistry of the Nucleus Accumbens and its Relevance to Depression and Antidepressant Action in Rodents
Volume: 4 Issue: 4
Author(s): Yukihiko Shirayama and Shigeyuki Chaki
Affiliation:
Keywords: Depression, nucleus accumbens, glutamate, dopamine, γ-aminobutyric acid (GABA), acetylcholine, dynorphin, cAMP response element-binding protein (CREB)
Abstract: There is accumulating evidence that the nucleus accumbens (NAc) plays an important role in the pathophysiology of depression. Given that clinical depression is marked by anhedonia (diminished interest or pleasure), dysfunction of the brain reward pathway has been suggested as contributing to the pathophysiology of depression. Since the NAc is the center of reward and learning, it is hypothesized that anhedonia might be produced by hampering the function of the NAc. Indeed, it has been reported that stress, drug exposure and drug withdrawal, all of which produce a depressive-phenotype, alter various functions within the NAc, leading to inhibited dopaminergic activity in the NAc. In this review, we describe various factors as possible candidates within the NAc for the initiation of depressive symptoms. First, we discuss the roles of several neurotransmitters and neuropeptides in the functioning of the NAc, including dopamine, glutamate, γ-aminobutyric acid (GABA), acetylcholine, serotonin, dynorphin, enkephaline, brain-derived neurotrophic factor (BDNF), cAMP response element-binding protein (CREB), melanin-concentrating hormone (MCH) and cocaine- and amphetamine-regulated transcript (CART). Second, based on previous studies, we propose hypothetical relationships among these substances and the shell and core subregions of the NAc.
Export Options
About this article
Cite this article as:
Shirayama Yukihiko and Chaki Shigeyuki, Neurochemistry of the Nucleus Accumbens and its Relevance to Depression and Antidepressant Action in Rodents, Current Neuropharmacology 2006; 4 (4) . https://dx.doi.org/10.2174/157015906778520773
DOI https://dx.doi.org/10.2174/157015906778520773 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy
Current Drug Metabolism Aging Changes in Satellite Cells and Their Functions
Current Aging Science Modified-Release Solid Formulations for Colonic Delivery
Recent Patents on Drug Delivery & Formulation Osteogenic Differentiation Factors of Multipotent Mesenchymal Stromal Cells in the Current Understanding
Current Pharmaceutical Design Evaluation of Treatment Tolerability, Satisfaction and Laboratory Parameters in HIV+ Patients Switching from Ritonavir Capsule to Tablet Formulation§
Current HIV Research CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Inducible Nitric Oxide Synthase Inhibition by Mycophenolic Acid
Mini-Reviews in Medicinal Chemistry Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery The Comorbidity of Bipolar Disorder and Migraine: The Role of Inflammation and Oxidative and Nitrosative Stress
Current Molecular Medicine Endogenous Bufadienolide, Blood Pressure and Alcohol Withdrawal
Current Hypertension Reviews Potential Therapeutic Effects of Exercise to the Brain
Current Medicinal Chemistry Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Forkhead Box O1-p21 Mediates Macrophage Polarization in Postoperative Cognitive Dysfunction Induced by Sevoflurane
Current Neurovascular Research Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Joint Application of <i>Magnetic Resonance Imaging</i> and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis
Current Medicinal Chemistry Prediction of Cell Wall Lytic Enzymes Using Chous Amphiphilic Pseudo Amino Acid Composition
Protein & Peptide Letters Xenobiotic-Metabolizing Enzymes in Human Lung
Current Drug Metabolism Body-centred and Object-centred Motor Imagery in Alzheimer's Disease
Current Alzheimer Research Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design